Kornimate/medical-research-clean huggingface dataset:
effects of a personalized physical training to reduce fatigue

Conditions: Fatigue Syndrome, Chronic

Summary: chronic fatigue (cf) is a pathological fatigue over at least 6 months, without improvement after rest or sleep. in primary care, it is the major complaint in 5 to 10% of the consultations. physical activity is an efficient therapy to help reducing this fatigue in addition to the improvement of muscular and cardiorespiratory functions. however, it remains little exploited. yet the studies focus mainly on precise chronic pathologies with general trainings, without considering the fatigue status and reveal a large heterogeneity. personalizing the physical training appears to be the next step in order to improve chronic fatigue patients care. the objective of this study will be to investigate the relevance and the effects of a personalized physical training to reduce fatigue in chronic fatigue patients.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 * men or women * facit-f score ≤ 34 * ability to walk during 10 minutes without stopping * ability to receive the myocene® stimulation protocol * have given written consent * members or beneficiaries of a social security program exclusion criteria: * contraindication to experimental procedures * important health issues that would compromise the participant security during the study * persistent atrial fibrillation or 2nd or 3rd degree atrioventricular block * currently participating in an other interventional study or having so in the past thirty days * patient is pregnant * patient is unable to give an informed consent * patient is deprived of liberty or under guardianship

Keywords: fatigue neuromuscular function personalized training physical capacity fatigue status
how does cerebellar tdcs alter intracortical inhibition over time?

Conditions: Stroke

Summary: combining cortical tdcs with behavioral interventions has been shown to have beneficial outcomes in individuals post-stroke. however, cerebellar tdcs is a fairly new approach for individuals with unilateral cortical stroke and there has not been reports of duration of effect of tdcs applied to the cerebellum in this population. information gained from this study will serve to fill knowledge gaps on the duration of effect of cerebellar tdcs and the effects of polarity. the purpose of this study is to determine the duration of effect of ventro-lateral cerebellar transcranial direct current stimulation (tdcs) in healthy adults through cortical excitability (ce), cognitive, language and motor assessment measures. primary aim: compare baseline ce from left motor cortex of first dorsal interosseous (fdi) and orbicularis oris (oo) areas to ce post cerebellar tdcs at 15 minutes, 45 minutes and 75 minutes. single-pulse and paired-pulse transcranial magnetic stimulation (tms) will be used to measure and compare stimulus response curve (s/r curve), cortical silent period (csp) and short-interval intracortical inhibition (sici) in the hand area and facial area of the left primary motor cortex at each time point. secondary aim: compare baseline performance on cognition, motor learning and language tasks to performance at 15, 45 and 75 minutes after receiving tdcs. digit symbol substitution test (dsst), serial reaction time test (srtt) and lexical decision tasks will be presented via a computer interface.


Eligibility criteria:
inclusion criteria: * eligible participants must be over the age of 18 years of age * must be fluent in english * have adequate vision to see a computer screen from 12-18 inches, fine motor skills to press a key on a computer keyboard and hearing to hear directions and questions provided by the researcher * individuals must also be able to read words and phrases exclusion criteria: * pregnancy * history of seizures * neurologic injury including concussion/head injury or stroke or other neurologic conditions * history of documented learning disabilities and/or adhd * metal implants in the body (excluding dental fillings), psoriasis or eczema affecting the scalp.
trial of adjuvant sutent for patients with high risk urothelial carcinoma after neoadjuvant chemotherapy and cystectomy

Conditions: Urothelial Carcinoma; Bladder Cancer

Summary: the purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal). a 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal. the patients are followed up to 2 years.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of bladder carcinoma (\>50% urothelial carcinoma) * prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy * prior treatment with radical cystectomy revealing pt3nxm0 or ptanyn+m0 * ecog performance status of 0-1 (appendix 2). * no evidence of metastases within 4 weeks of registration * adequate organ and marrow function obtained within 14 days of registration exclusion criteria: * severe or uncontrolled acute or chronic medical or psychiatric condition * prior antiangiogenic therapy * prior pelvic radiation for bladder cancer

Keywords: sunitinib bladder neoplasm adjuvant treatment disease free survival cystectomy
non-pharmaceutical intervention for cirrhotic cramps reduction: the niccles trial

Conditions: Cirrhosis; Muscle Cramp; Ascites

Summary: this clinical trial is evaluating the feasibility of using a non-pharmaceutical treatment to improve the symptoms and severity of muscle cramps in patients with cirrhosis. eligible participants will be randomized to the treatment arm or control group. the treatment phase of the study will last 28 days. information about participants will be collected including surveys and assessments throughout the study. please note that only the participants randomized to experimental intervention group (household remedy) will be told what the treatment is during the study period. at the conclusion of the study (time of the final follow-up assessments), all participants will be debriefed on the use of concealment in this study as outlined in the protocol regarding the intervention.


Eligibility criteria:
inclusion criteria: * diagnosis of cirrhosis (criteria per protocol will be used) * history of painful muscle spasms, cramps, or charley horses that come on while resting (they had to have happened 4 times in the past month and bother the participant) exclusion criteria: * non-english speaking * unable or unwilling to provide consent * history of liver transplant * history of multiple sclerosis * history of cerebral palsy * history of stroke with paralysis

Keywords: liver disease nutrition quality of life sleep non-pharmaceutical intervention
confocal laser endomicroscopy with topical cresyl violet for colorectal polyps

Conditions: Colorectal Polyps

Summary: probe-based confocal laser endomicroscopy (pcle) has been shown to a reliable diagnostic method enabling in vivo microscopic imaging during ongoing endoscopy. usually fluorescein then serves as a contrast agent for pcle, but it does not allow direct nuclear visualization, must be injected, leads to a transient skin discoloration, and may have allergic side effects. this study aimed to establish a single topical dye, cresyl violet (cv) for pcle imaging, to describe pcle interpretation criteria for the characterization of colorectal polyps with histopathological correlation, and to perform the validation of these criteria.


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 75 years, with polyps found during surveillance or screening colonoscopies. exclusion criteria: * contraindications to cv (such as allergy); * pregnancy or breastfeeding; * serous cardiopulmonary diseases, severe coagulopathy dysfunction, impaired kidney function; * inability to provide informed consent.
online aerobic therapeutic exercise program for patients with limitation of personality

Conditions: Borderline Personality Disorder

Summary: introduction: borderline personality disorder is a serious mental illness with high prevalence and difficult to diagnose. bpd is characterized by unstable relationships, distorted sense of self, emotional instability and a strong impulsiveness with weak impulse control. physiotherapy in mental health, currently being developed, is considered potentially effective in order to improve physical and mental health and the quality of life related to health. objective: the main objective of this study is to analyze the effect of an aerobic therapeutic exercise plan in the quality of life of patients with bdp. methodological design: a random controlled critical trial is going to be carried out. a sample of 50 participants diagnosed with bpd, aged 18 years and older, will be taken. they will be divided randomly in two groups: control group and treatment group. the treatment group will carry out a program of aerobic exercise twice a week for five weeks divided in four defined levels of variable length. the variables that will be compared before and after the intervention are: seriousness according to symptomatology, depression and anxiety level, emotion regulation difficulty, life quality level, physical condition level and ability of effort. after the intervention, the results will be analyzed by means of statistical processing based on the data obtained.


Eligibility criteria:
inclusion criteria: * men or women, diagnosed with borderline personality disorder according to dsm-v with moderate-high severity who are admitted to a care center 24 hours a day. * people over 18 years of age. * people who do not perform scheduled physical exercise. * have electronic means (computer / tablet / mobile) with an internet connection, as well as the cognitive and motor skills necessary to carry out the proposed exercises. exclusion criteria: * people with intellectual or physical disabilities that prevent them from carrying out the intervention. * people with heart or respiratory problems that prevent them from doing physical exercise. * people who are legally incapacitated. * not meeting the inclusion criteria.

Keywords: border personality disorder physiotherapy aerobic exercise emotional regulation teleassitence
a randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of cmv disease in people infected with the human immunodeficiency virus

Conditions: Cytomegalovirus Infections; HIV Infections

Summary: to evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (cmv) disease (e.g., cmv retinitis, gastrointestinal cmv disease) in cmv-infected people with hiv infection and cd4 lymphocyte counts \<= 100 cells/mm3. to evaluate the efficacy of this drug in reducing morbidity associated with coinfection by both cmv and hiv.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * topical or ophthalmic nucleoside analogs. patients must have: * confirmation of hiv infection. * documented cmv infection. * no past or present cmv disease (e.g., retinitis, colitis, esophagitis). * adequate visualization of the retina of both eyes by ophthalmologist. * cd4 count \<= 50 cells/mm3 (in patients without a history of an aids-defining opportunistic infection or chronic gynecologic infection) or cd4 count \<= 100 cells/mm3 (in patients with a history of an aids-defining opportunistic infection or chronic gynecologic infection). exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * presence of gastrointestinal disease or symptoms not controlled with medications (e.g., persistent nausea, abdominal pain or persistent diarrhea within the past 4 weeks that is not controllable with medication). * inability to comply with protocol. concurrent medication: excluded: * the following nucleoside analogs: * iv ganciclovir, iv acyclovir for more than 2 weeks total duration, oral acyclovir at doses \> 1000 mg/day, vidarabine, amantadine hydrochloride, cytarabine, idoxuridine. * fiau, fiac, foscarnet, cmv hyperimmune globulin, iv immune globulin, cmv monoclonal antibody, hpmpc. * imipenem-cilastatin (primaxin). patients with the following prior condition are excluded: history of hypersensitivity to acyclovir. prior medication: excluded within the past 60 days: ganciclovir, foscarnet, fiac, fiau, cmv hyperimmune globulin, cmv monoclonal antibody, or hpmpc.

Keywords: ganciclovir cytomegalovirus infections acquired immunodeficiency syndrome
self-management of patients with acute coronary syndromes

Conditions: Acute Coronary Syndromes

Summary: purpose : the purpose of this study is to investigate the tracking effect of selfmanagement programs on anxiety, depression, and quality of life in patients with acute coronary syndromes (acs).

research design : this study the first phase is to construct and develop interventional measures for self-management of patients with acs. according to the associated factors of study, the intervention measures are designed based on self-management. a pilot study will be conducted to improve research and to develop better selfmanagement interventions in the future. at the secondary stage: a randomized controlled trial with a random sampling design is used to investigate the effects of self-management programs on anxiety, depression, and quality of life in patients with acs. the study will conduct in a cardiac medicine ward or coronary intensive care center of a north medical center. patients with acs,who met the conditions and agreed to join the study will be recruited. then,the informed consent will be obtained. at the first stage, 10subjects will be collect. at the secondary stage, a total of 104 subjects will be enrolled, 52 in the experimental group will receive the self-management program, and 52 in the control group will receive a routine hospital care. method \& results: the data of demographic and disease characteristics, clinical indicators,depression, anxiety, self-management, and quality of life will be collected.the hospital anxiety and depression scale, the sf-36 taiwan version of the quality-of-life questionnaire and the self-management scale will used as tools to collect data. the efficacy of the intervention will be collected 1 month and 3 months after the intervention. data will be statistically analyzed by gee. hypothesis : it is expected that the self-management program applied to patients with acs can reduce depression and anxiety, thereby improving the quality of life.

Eligibility criteria:
inclusion criteria: * over 20 years old * the first diagnosis of acute coronary syndrome by a clinician, * clear consciousness, able to converse in chinese and taiwanese languages. * willingness to participate in this research exclusion criteria: * those who are unable to take care of themselves * poor vision and inability to read * hard of hearing and deafness * inability to communicate

Keywords: self-management acute coronary syndrome anxiety depression quality of life
triathlon pkr study in japan

Conditions: Osteoarthritis of the Knee

Summary: the purpose of this study is to evaluate compatibility of the triathlon partial knee replacement (pkr) with the japanese population. it is expected that patients who receive the triathlon pkr will achieve excellent clinical results without adverse effects and that the device fits well with japanese morphology.


Eligibility criteria:
inclusion criteria: 1. patient requires a primary unicompartmental knee replacement. 2. patient is between 20 years old to 80 years old. 3. patient is diagnosed as osteoarthritis, rheumatoid arthritis, traumatic arthritis or avascular necrosis. 4. patient can walk independently at least 10m. 5. patient has signed the institutional review board (irb) approved, study specific informed patient consent form. 6. patient is willing and able to comply with post-operative scheduled clinical and radiographic evaluations and rehabilitation. exclusion criteria: 1. patient requires a revision. 2. patient is pregnant. 3. patient has lateral osteoarthritis. 4. patient has less than 10°of flexion contracture and greater than 90°of flexion. 5. patient's preoperative mechanical alignment is less than 10° of varus and 15° of valgus. 6. patient has had high tibial osteotomy, femoral osteotomy and/or joint fusion. 7. patient has a neuromuscular or neurosensory deficiency that would limit the ability to assess the performance of the device. 8. patient has a systemic or metabolic disorder leading to progressive bone deterioration. 9. patient is immunologically suppressed or receiving steroids (\>30 days) in excess of normal physiological requirements. 10. patient has a deformity which will require the use of wedges or augments. 11. patient has an active or suspected latent infection in or about the knee joint. 12. patient who is inappropriate for participating in the study by the judgment of the investigator.
brain characteristics noted prior to and following treatment

Conditions: Nonsynostotic Plagiocephaly

Summary: this study will enable investigators to find out if brain structure and characteristics are affected by the shape of the infant's head, and if changes in the brain occur with helmet therapy.

a dramatic increase in the number of infants diagnosed with deformational plagiocephaly (dp) has been observed worldwide since institution of the american academy of pediatrics' back to sleep program. according to one published report, the incidence of dp ranges between 3-48%; this translates into120,000-2 million infants/year who develop dp in the united states alone. some healthcare providers believe that dp is a purely cosmetic condition. this mindset undermines the importance of prevention and correction. in new zealand, a recent study demonstrated that 39% of children without corrective action had persistent dp at age 3 to 4 years. additionally, several studies have demonstrated associations between impaired social interactions, developmental problems and dp.thus some researchers now believe that there may be a spectrum of untoward outcomes from brain remodeling resulting from dp. recent technological advances now allow the detection of diminutive changes in brain structure. in this multidisciplinary descriptive pilot study we will use brain mri (magnetic resonance imaging) and a cerebral tissue oxygenation monitor, namely frequency domain near infrared and diffuse correlation spectroscopy (fdnir/dcs) to describe if differences in brain structure and characteristics exist in infants with significant dp before and after correction of the deformational defect. this study will enable investigators to seek preliminary evidence that brain development is influenced by the shape of the cranial vault, and that changes in brain structure and characteristics occur with helmet therapy. additionally this study will help to determine the need for a larger investigation of this phenomenon that would further establish an association between dp and developmental delay.

Eligibility criteria:
inclusion criteria: 1. - dp requiring helmet therapy 2. -term gestation at birth (37 weeks or greater) 3. -less than/or equal to 8 months of age 4. -no history of major health problem such as birth injury, genetic disorder, intracranial hemorrhage, hydrocephalus, neurologic abnormality 5. -no history of implantable metal device or internal/external orthotic device exclusion criteria: 1. - dp not requiring helmet therapy 2. -premature gestation at birth (less than 37 weeks gestation). 3. -greater than 8 months of age 4. -history of major health problem such as birth injury genetic disorder, intracranial hemorrhage, hydrocephalus, neurologic abnormality 5. -history of implantable metal device or internal/external orthotic device 6. -infants not completing prescribed treatment for correction with a helmet

Keywords: plagiocephaly
leaders free iii: biofreedom™ clinical trial

Conditions: Cardiac Death; Myocardial Infarction; Stent Thrombosis; Bleeding; Mortality

Summary: a study evaluating the safety and efficacy of the biofreedom™ biolimus a9™ coated cobalt chromium coronary stent system in patients at high risk of bleeding

prospective, multi-center, open-label single-arm study designed to enroll 370 hbr patients (for at least 340 evaluable) at up to 20 centers in up to 2 european countries. 370 patients will receive a biofreedomtm cocr stent. all patients will be followed up for 2 years.

Eligibility criteria:
inclusion criteria: * patients at high bleeding risk (hbr) with an indication for percutaneous coronary intervention who can tolerate no more than one month of dapt. this includes candidates with stable angina, silent ischemia, acs (stemi and non-stemi), non-native lesions and in-stent restenosis. patients must provide written informed consent. reasons of unsuitability for \> 1 month dual antiplatelet treatment must include one or more of the following: 1. adjunctive oral anticoagulation treatment planned to continue after pci 2. age ≥ 75 years old 3. baseline hgb \<11 g/dl (or anemia requiring transfusion during the 4 weeks prior to inclusion into the trial) 4. any prior intracerebral bleed 5. any stroke in the last 12 months 6. hospital admission for bleeding during the prior 12 months 7. non skin cancer diagnosed or treated ≤ 3 years 8. planned daily nsaid (other than aspirin) or steroids for ≥ 30 days after pci 9. planned surgery that would require interruption of dapt (within next 12 months) 10. renal failure defined as: creatinine clearance \<40 ml/min 11. thrombocytopenia (plt \<100,000/mm3) 12. severe chronic liver disease defined as: patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice 13. expected non-compliance to prolonged dapt for other medical reasons exclusion criteria: 1. pregnant and breastfeeding women 2. patients expected not to comply with 1 month dapt 3. patients requiring a planned staged pci procedure more than one week after the index procedure 4. procedure requires the use of non-study stents, or alternative therapeutic options not followed by stent implantation (angioplasty only, atherectomy only). 5. active bleeding at the time of inclusion 6. if patient requires a stent \<2.5mm 7. if patient requires a stent \>3.5mm 8. cardiogenic shock 9. compliance with long-term single anti-platelet therapy unlikely 10. known hypersensitivity or contraindication to aspirin, clopidogrel (or to any another p2y12 inhibitor if applicable), cobalt chromium, zinc, biolimus a9tm or a sensitivity to contrast media, which cannot be adequately pre-medicated 11. pci during the previous 12 months for a lesion other than the target lesion 12. participation in another clinical trial (12 months after index procedure) 13. patients with a life expectancy of \< 1 year
optimising congestive heart failure outpatient clinic project

Conditions: Heart Failure

Summary: this study examines whether a nurse monitored management program at the hospital heart failure outpatient clinic can improve quality of life in elderly patients with chronic heart failure, as compared to standard treatment in primary healthcare.

patients 60 years of age or more hospitalized with heart failure according to new york heart association (nyha) class ii-iv and systolic dysfunction (left ventricular ejection fraction less than 0.45) are investigated before discharge and than randomized to the nurse monitored management program or to standard care. examinations are performed at 0, 6, 12, and 18 months, and include clinical signs and symptoms, quality of life, biochemical assessment, echocardiography and drugs used. the study will be completed when all patients have passed the 18 month follow up examination. quality of life is assessed by the nottingham health profile.

Eligibility criteria:
inclusion criteria: * patients 60 years of age or older * hospitalized with heart failure according to new york heart association (nyha) class ii-iv * left ventricular systolic dysfunction with an ejection fraction below 0.45, by echocardiography exclusion criteria: * an acute myocardial infarction or unstable angina pectoris within the last three months * valvular stenosis * dementia * severe concomitant disease * refusal to participate.

Keywords: heart failure quality of life